| Christine Elizabeth O'connor, NURSE PRACTITIONER | |
|
332 Hanover St, Boston, MA 02113 | |
| (617) 643-8080 | |
| Not Available |
| Full Name | Christine Elizabeth O'connor |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 332 Hanover St, Boston, Massachusetts |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003361551 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North End Community Health Committee, Inc. | 8224043971 | 43 |
News Archive
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator" gene may be the key to developing a new treatment for tumors resistant to current drugs.
Fitch Ratings has downgraded to 'C' from 'CC' the rating on approximately $45.5 million of bonds (listed below) issued by Valley Health System, California (VHS). In addition, Fitch has placed the bonds on Rating Watch Negative.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
› Verified 7 days ago
| Entity Name | North End Community Health Committee, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780606608 PECOS PAC ID: 8224043971 Enrollment ID: O20060216000209 |
News Archive
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator" gene may be the key to developing a new treatment for tumors resistant to current drugs.
Fitch Ratings has downgraded to 'C' from 'CC' the rating on approximately $45.5 million of bonds (listed below) issued by Valley Health System, California (VHS). In addition, Fitch has placed the bonds on Rating Watch Negative.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine Elizabeth O'connor, NURSE PRACTITIONER 332 Hanover St, Boston, MA 02113-1901 Ph: (617) 643-8080 | Christine Elizabeth O'connor, NURSE PRACTITIONER 332 Hanover St, Boston, MA 02113 Ph: (617) 643-8080 |
News Archive
Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator" gene may be the key to developing a new treatment for tumors resistant to current drugs.
Fitch Ratings has downgraded to 'C' from 'CC' the rating on approximately $45.5 million of bonds (listed below) issued by Valley Health System, California (VHS). In addition, Fitch has placed the bonds on Rating Watch Negative.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
› Verified 7 days ago
Kristen Cahill, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 600 Washington St, Boston, MA 02111 Phone: 508-685-8452 | |
Mrs. Patricia Noreen Finneran, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 15 Parkman St, Wac 440, Boston, MA 02114 Phone: 617-643-4709 | |
Miss Megan Elizabeth Smetana, RN, CPNP-AC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Cardiology, Boston, MA 02115 Phone: 617-355-8689 | |
Mr. Courtney Sullivan Fratto, CPNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Hunnewell Building 322, Boston, MA 02115 Phone: 857-218-4085 | |
Ms. Kelly Elisha Trecartin, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 55 Fruit St, Bigalow 852 F, Boston, MA 02114 Phone: 617-726-7400 Fax: 617-726-4149 | |
Mrs. Melissa Ashley Ziogas, APRN-FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 133 Brookline Ave, Boston, MA 02215 Phone: 617-421-1000 | |
Jamie Marie Allen, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 55 Fruit St, Boston, MA 02114 Phone: 617-724-4410 |